This “Pericarditis - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Pericarditis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Pericarditis is characterized by swelling and irritation in the pericardial sac, and often a pericardial effusion. The condition causes sharp chest pain when the irritated pericardium layer rub against each other. It can be grouped into different categories which include acute pericarditis, recurrent pericarditis, incessant, and chronic constrictive pericarditis. Pericarditis occurs in people of all ages, although viral pericarditis is more common in adults than in children. In contrast, purulent pericarditis is common in children. Although, pericarditis is usually mild and does not require treatment however, more severe cases may include medications such as colchicine, pain relievers, corticosteroids and surgeries in very rare cases.
"Pericarditis - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pericarditis pipeline landscape is provided which includes the disease overview and Pericarditis treatment guidelines. The assessment part of the report embraces, in depth Pericarditis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pericarditis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
This segment of the Pericarditis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
There are approx. 3+ key companies which are developing the therapies for Pericarditis. The companies which have their Pericarditis drug candidates in the most advanced stage, i.e. phase pre-registration include, Kiniska Pharmaceuticals.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pericarditis therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pericarditis drugs.
Geography Covered
- Global coverage
Pericarditis Understanding
Pericarditis: Overview
Pericarditis is characterized by swelling and irritation in the pericardial sac, and often a pericardial effusion. The condition causes sharp chest pain when the irritated pericardium layer rub against each other. It can be grouped into different categories which include acute pericarditis, recurrent pericarditis, incessant, and chronic constrictive pericarditis. Pericarditis occurs in people of all ages, although viral pericarditis is more common in adults than in children. In contrast, purulent pericarditis is common in children. Although, pericarditis is usually mild and does not require treatment however, more severe cases may include medications such as colchicine, pain relievers, corticosteroids and surgeries in very rare cases.
"Pericarditis - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pericarditis pipeline landscape is provided which includes the disease overview and Pericarditis treatment guidelines. The assessment part of the report embraces, in depth Pericarditis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pericarditis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Pericarditis R&D. The therapies under development are focused on novel approaches to treat/improve Pericarditis.
Pericarditis Emerging Drugs Chapters
This segment of the Pericarditis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pericarditis Emerging Drugs
- Rilonacept: Kiniska Pharmaceuticals
- RPH-104: R Internat-Pharm ional, LLC
Pericarditis: Therapeutic Assessment
This segment of the report provides insights about the different Pericarditis drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Pericarditis
There are approx. 3+ key companies which are developing the therapies for Pericarditis. The companies which have their Pericarditis drug candidates in the most advanced stage, i.e. phase pre-registration include, Kiniska Pharmaceuticals.
The report covers around 3+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Pericarditis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Pericarditis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pericarditis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pericarditis drugs.
Pericarditis Report Insights
- Pericarditis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Pericarditis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Pericarditis drugs?
- How many Pericarditis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pericarditis?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pericarditis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Pericarditis and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Kiniska Pharmaceuticals
- R-Pharm International, LLC
Key Products
- Rilonacept
- RPH-104
Table of Contents
IntroductionExecutive Summary
Pericarditis: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Pericarditis - Analytical Perspective
In-depth Commercial Assessment
- Pericarditis companies' collaborations, Licensing, Acquisition - Deal Value Trends
Pericarditis Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Pre-registration)
- Comparative Analysis
Rilonacept: Kiniska Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
Late Stage Products (Phase II/III)
- Comparative Analysis
RPH-104: R-Pharm International, LLC
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Pericarditis Key Companies
Pericarditis Key Products
Pericarditis - Unmet Needs
Pericarditis - Market Drivers and Barriers
Pericarditis - Future Perspectives and Conclusion
Pericarditis Analyst Views
Pericarditis Key Companies
AppendixList of Tables
Table 1 Total Products for Pericarditis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Pericarditis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Kiniska Pharmaceuticals
- R-Pharm International, LLC
